GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (OTCPK:BFFTF) » Definitions » Cyclically Adjusted PS Ratio

BFFTF (Biofrontera AG) Cyclically Adjusted PS Ratio : 0.77 (As of Sep. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biofrontera AG Cyclically Adjusted PS Ratio?

As of today (2024-09-25), Biofrontera AG's current share price is $22.68. Biofrontera AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $29.31. Biofrontera AG's Cyclically Adjusted PS Ratio for today is 0.77.

The historical rank and industry rank for Biofrontera AG's Cyclically Adjusted PS Ratio or its related term are showing as below:

BFFTF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.24   Med: 3.24   Max: 9.46
Current: 0.25

During the past years, Biofrontera AG's highest Cyclically Adjusted PS Ratio was 9.46. The lowest was 0.24. And the median was 3.24.

BFFTF's Cyclically Adjusted PS Ratio is ranked better than
92.59% of 648 companies
in the Drug Manufacturers industry
Industry Median: 2.31 vs BFFTF: 0.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biofrontera AG's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.252. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $29.31 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biofrontera AG Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Biofrontera AG's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Cyclically Adjusted PS Ratio Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.82 4.07 3.94 0.92

Biofrontera AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.06 1.27 0.92 0.77

Competitive Comparison of Biofrontera AG's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Cyclically Adjusted PS Ratio falls into.



Biofrontera AG Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Biofrontera AG's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.68/29.31
=0.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Biofrontera AG's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.252/125.0381*125.0381
=1.252

Current CPI (Mar. 2024) = 125.0381.

Biofrontera AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.612 99.543 0.769
201409 0.764 99.823 0.957
201412 0.994 99.543 1.249
201503 0.815 99.717 1.022
201506 0.520 100.417 0.647
201509 0.825 100.417 1.027
201512 1.224 99.717 1.535
201603 0.758 100.017 0.948
201606 0.475 100.717 0.590
201609 0.808 101.017 1.000
201612 2.333 101.217 2.882
201703 1.424 101.417 1.756
201706 1.418 102.117 1.736
201709 1.346 102.717 1.638
201712 2.929 102.617 3.569
201803 2.845 102.917 3.457
201806 1.950 104.017 2.344
201809 2.858 104.718 3.413
201812 3.268 104.217 3.921
201903 3.424 104.217 4.108
201906 3.768 105.718 4.457
201909 2.476 106.018 2.920
201912 5.915 105.818 6.989
202003 3.658 105.718 4.327
202006 4.072 106.618 4.776
202009 2.421 105.818 2.861
202012 2.892 105.518 3.427
202103 2.419 107.518 2.813
202106 3.250 108.486 3.746
202109 2.242 109.435 2.562
202112 2.814 110.384 3.188
202203 2.585 113.968 2.836
202206 3.956 115.760 4.273
202209 2.505 118.818 2.636
202212 1.414 119.345 1.481
202303 2.044 122.402 2.088
202306 4.274 123.140 4.340
202309 2.503 124.195 2.520
202312 2.560 123.773 2.586
202403 1.252 125.038 1.252

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biofrontera AG  (OTCPK:BFFTF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Biofrontera AG Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG Headlines